Coronavirus vaccine production is under threat due to US export controls.
According to the Financial Times, such statements were made by representatives of the Indian manufacturers of the drug AstraZeneca and Johnson & Johnson.
In particular, Mahim Datla, executive director of the pharmaceutical company Biological E, announced a warning from American suppliers. According to him, this will complicate the production of vaccines, including those against coronavirus. US companies report the possibility of contract disruptions with overseas clients due to the war production law.
Serum Institute executive director Adar Punavalla agreed with this opinion. He expressed confidence that US war production law could undermine global vaccination efforts. “The Novavax vaccine, of which we are the largest manufacturers, needs these products from the USA. We are talking about having free global access to vaccines, but if we cannot get the raw materials out of the United States, this will become a serious limiting factor”, he explained.
The problem is that the vaccine requires raw materials that only a few companies produce.
The War Production Act was passed in the United States in 1950. It allows the authorities to force businesses to fulfill primarily government orders.
In April last year, Donald Trump signed a decree on the application of this law for the production of ventilators, masks and other goods necessary to combat COVID-19. The same document was among the first decrees of the current President Joe Biden.